Related references
Note: Only part of the references are listed.Quiescent Tissue Stem Cells Evade Immune Surveillance
Judith Agudo et al.
IMMUNITY (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
Jing Liao et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Toll-like receptor (TLR) 7 expression in mycosis fungoides and psoriasis: a case-control study
A. M. El Tawdy et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
Marie de Charette et al.
EUROPEAN JOURNAL OF CANCER (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment
Nina Chevalier et al.
LEUKEMIA & LYMPHOMA (2016)
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma
Stefani Spranger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
Alain H. Rook et al.
BLOOD (2015)
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers
N. Anandasabapathy et al.
BONE MARROW TRANSPLANTATION (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
Christian Thomas Mayer et al.
BLOOD (2014)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Ronald Levy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Classical Flt3L-dependent dendritic cells control immunity to protein vaccine
Niroshana Anandasabapathy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Martin Guilliams et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H. Kim et al.
BLOOD (2012)
Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation
Annabell Bachem et al.
FRONTIERS IN IMMUNOLOGY (2012)
Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer
Kathleen Anders et al.
CANCER CELL (2011)
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High-mobility group box 1 and cancer
Daolin Tang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Hideyuki Yanai et al.
NATURE (2009)
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
David Sancho et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
Kai Hildner et al.
SCIENCE (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Distribution patterns of dendritic cells and T cells in Diffuse large B-cell lymphomas correlate with prognoses
Kung-Chao Chang et al.
CLINICAL CANCER RESEARCH (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
The ability of natural tolerance to be applied to allogeneic tissue: determinants and limits
William F. N. Chan et al.
BIOLOGY DIRECT (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes
Kristian M. Hargadon et al.
JOURNAL OF IMMUNOLOGY (2006)
Critical roles of interferon regulatory factor 4 in CD11bhighCD8α- dendritic cell development
S Suzuki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8α+ dendritic cells
G Schiavoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
FIG ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers
ML Disis et al.
BLOOD (2002)
Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
C Gasparetto et al.
CYTOKINE (2002)
In vivo manipulation of dendritic cells to induce therapeutic immunity
M Merad et al.
BLOOD (2002)
Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses
MC Wolkers et al.
JOURNAL OF IMMUNOLOGY (2001)
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo
D Hawiger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
AF Ochsenbein et al.
NATURE (2001)
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer
MA Morse et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
B Sauter et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)